Contraception pe 1997;55:38 1-382 5 Ot YS I ELSEVIER Author Index Volume 55 January-June 1997 Aiying, W., 15 del Carmen Cravioto, M., 359 Katz, D.F., 115, 209 Kay, C.R., 145 Alexander, N.J., 261 DelConte, A., 139 Alihonou, E., 97 Diaz, J., 307 Kennedy, K.I., 347 Alvarado, G., 359 Diaz, S., 73, 81, 225 Khamis, Y., 7 Khan, H.T.A., 91 Alvarez, F., 81, 225 Byaz. S225 Anant, M.P., 73 Diez, M.J., 47 Khan-Dawood, F.S., 233 Du, M.-K., 225 Archer, D.F., 139 Kiode, S.S., 35 Dunmire, E.N., 115, 209 Kiriwat, O., 73 Bahamondes, L., 307 Diisterberg, B., 131 Klaisle, C., 81 Barbosa, I., 175 Knudsen, L.B., 301 Bardin, C.-W., 35 el din Abdalla, K., 73 Koctsawang, S., 73, 81, 225 Barditch-Crovo, 261 El-Sawi, M., 7 Kosunen, E., 153 Barraza-Vasquez, A., 311 Endrikat, J., 131 Kriiger Kjaer, S., 287 Bartenstein, P., 87 Basnayake, S., 225 Labbok, M.H., 323, 327, 337 Farahmand, S., 19 Bassol, S., 311, 359 Lacarra, M., 81, 225 Bastianelli, C., 295 Felix, J.C., 19 LaGuardia, K., 81 Fernandez, C., 165 Belsey, E.M., 57 Lahteenmaki, P., 81 Fernandez, N., 47 Belsey, M., 323 Lanzetta, D. 239 Fletcher, V., 327, 337 Benegiano, G., 295 Lasa, L.I., 53 Foldesy, R., 169 Bianchi, P., 295 Lasley, B.L., 103 Bihareus, P., 81 Fuziwara, J.L., 359 Lavin, P., 307 Bloemenkamp, K.W.M., 189 Leal, C., 175 Bock, J.E., 287 Gammon, M.D., 197 Ledger, W.J., 23 Botterman, P., 87 Ganguli, N.K., 315 Leonard, R.J., 23 Levine, A.B., 53 Brache, V., 81, 225 Garcia, J.J., 47 Brinton, L.A., 197 Garza-Flores, J., 359 Lewis, M.A., 189 Gatto, M., 175 Li, X.-J., 35 Canto-de-Cetina, T., 359 Gbolade, B.A., 319 Lynam, P.F., 249 Campodonico, I., 73 Ghosh, D., 103 Capochichi, V., 97 Goldzieher, J.W., 233 Maheux, R., 139 Carbonell, J.L.L., 165 Grubb, G.S., 245 Malone, E., 197 Carr, BA, 267 Gupta, [., 315 Maradiegue, E., 307 Carre, N., 97 Mardh, P.-A., 355 Chaturachinda, K., 205, 283, 351 Hamzeh, F., 261 Marr, J., 145 Coates, R.J., 197 Hannaford, P.C., 145 Marzouk, S., 7 Coffin, C.j., 323 McCarthy, T., 225 Harman, S.M., 23 Coutinho, E.M., 175 McPherson, J., 261 Hartard, M., 87 Cowchock, S., 53 Hellberg, D., 355 Medda, E., 295 Crook, D., on behalf of the UK Mehanna, M.T.R., 7 Helmerhorst, F.M., 189 Study Group, 219 Mezrich, R.S., 169 Hemminki, E., 153 Croxatto, H.B., 225 Hight-Laukaran, 327, 337 Miranda, P., 225 Hippolito, $.B., 175 Mishell, Jr., D.R., 81, 225 Monteiro, I., 307 D’Antona, D., 239 Holma, P., 73 D’Aurea Abranches, A., 175 Morais, K., 175 Daling, J.R., 197 Moreno, J.E., 233 Intaraprasert, S., 205, 283, 351 Morgante, G., 239 Dao, B., 35 Miiller, U., 131 Darney, P., 81 de Barros Leal, W., 175 Jackanicz, T., 225 de Souza, R.N., 175 Jeschke, D., 87 Nair, K.M., 373 De Palma, P., 239 Jinsong, Q., 369 Nash, H., 81 De Leo, V., 239 Judrez-Perez, M.A., 245 Nava, M.P., 311 © 1997 Elsevier Science Inc. All rights reserved. ISSN 0010-7824/97/$17.00 655 Avenue of the Americas, New York, NY 10010 Pll S0010-7824(97)00092-9 382 Author Index Contraception 1997;55:38 1-382 Navarrete, T., 359 Ruminjo, J.K., 249 Toppozada, M.K., 7 Nayak, N.R., 103 Russer, T.J., 169 Trapnell, C.B., 261 Neto, J.S.P., 175 Tully, M.R., 347 Nilsson, S., 355 Santos-Yung, R., 359 Saxena, B.B., 23 UK Study Group, 219 Ojeda, G., 307 Sayed, E.H., 225 Valencia, J., 359 Oropeza, G., 359 Schoenberg, J.B., 197 Ory, H., 267 Schwaiger, M., 87 Vanage, G., 35 Vandenbroucke, J.P., 189 O’Brien, F.B., 139 Schwingl, P.J., 125 Van Look, P.F.A., 327, 337 Sengupta, J., 103 Varela, L., 165 Painter, R., 145 Shaaban, M., 225 Velazco, A., 165 Palma, Y., 359 Shaobo, X., 369 Pasquale, S.A., 169 Shatrugna, V., 373 Vessey, M.P., 145 Pavez, M., 73,81 Shelton, J., 125 VViieeggaass,, OO..,A .C73. , 81 Perada, P., 47 Short, R.V., 347 Villegas-Salas, E., 245 Pérez-Palacios, G., 359 Shoubnikova, M., 355 von Hertzen, H., 327, 337 Peterson, A.E., 327, 337 Sierra, M., 47 Petta, C., 307 Sihvo, S., 153 Wan, L., 73, 81 Phuapradit, W., 205 Singh, M., 23 Wei, Z., 15 Pinol, A.P.Y., 57 Sivakumar, B., 373 Weiss, N.S., 189 Piya-Anant, M., 81 Sivin, I., 73, 81, 225 Wiebe, E.R., 67, 159 Poll, P., 287 Skjeldstad, F.E., 11 Wielandt, H., Ponce de Leon, R., 245 Spinola, P., 175 Witter, F., 261 Pradhan, M., 315 Stanczyk, F.Z., 273 Wu, S.-C., 225 Primiero, F.M., 295 Stern, J., 73, 81, 225 Stratton, P., 261 Xiao, B;,.225 Qiming, X., 369 Svare, E.I., 287 Yang, Z., 15 Raghubanshi, R.S., 23 Taneepanichskul, S., 205, 283, Yazlle, M.E., 175 Ramadan, M.., 7 351 Yibin, S., 369 Teng, C.S., 41, 183 Ranta, S., 81 Yimin, C., 15 Ravinder, P., 373 Teran, T., 47 Ying, W., 369 Recio, R., 311 Thonneau, P., 97 Rosendaal, F.R., 189 Temaz; G., 175 Zhimin, L., 15 Contraception 0;0:383-385 ELSEVIER Subject Index Volume 55 January-June, 1997 Abortion seekers, contraceptive practices, 15 Cortisol levels, effect of Norplant implants, 7 Abortions related to adverse media coverage, 11 CUE® method, natural family planning, 233 Acceptability, Lactational Amenorrhea Method, 337 CuT380A IUD, interaction between magnetic Adverse media coverage, effect on induced resonance imaging, 169 abortions, 11 Amoxicillin-ethinylestradiol, pharmacokinetic interaction (rabbit), 47 Definitions of breastfeeding, 323 Anaphylactoid reaction, post Norplant implants Determinants for contraceptive use, 287 insertion, 319 Antifertility effect, LHRH antagonist (male rats), 369 Emergency contraception, knowledge and use, 153 Anti-implantation activity, RU 486 (monkey), 103 Endocrine function, effect of ethinyl estradiol + Antiprogestins + anordiol, pregnancy termination desogestrel, 219 (rat), 35 Endometrial glandular proliferation and hormone receptor status, 19 Estradiol cypionate + medroxyprogesterone acetate, Bacterial vaginosis, contraceptive use, 355 307 Biodegradable implants, clinical study, 23 Estradiol enanthate + dihydroxyprogesterone Birth control experience in Denmark, 301 acetophenide, clinical trial, 175 Bone mineral density, effect of exercise and OCs, 87 Estradiol valerate + norethisterone enanthate, 295 Breast cancer risk and OCs, 197 Estrogen receptor content and endometrial Breastfeeding, Lactational Amenorrhea Method, glandular proliferation, 19 327, 337 Ethinyl estradiol and amoxicillin, pharmacokinetic Breastfeeding definitions, 323 interaction (rabbit), 47 Buserelin, effect on male infants, 311 Ethinyl estradiol + desogestrel, 219 Ethinyl estradiol + gestodene, clinical trial, 131 Carbohydrate metabolism, Ethinyl estradiol + levonorgestrel, efficacy and effect of estradiol valerate + norethisterone safety study, 139 enantate, 295 Ethinyl estradiol + norethisterone, 295 effect of ethinylestradiol + norethisterone, 295 Ethinyl estradiol metabolism, influence of Cervical mucus, permeation of nonoxynol-9, 115 gestodene and desogestrel, 273 Citrulline, L-, level in copper IUD users, 315 Exercise and OC use, effect on bone mineral Clinical guidance, Lactational Amenorrhea Method, density, 87 327 Clinical trial, estradiol enanthate + dihydroxyprogesterone Family planning, Lactational Amenorrhea Method, acetophenide, 175 327, 337 ethinylestradiol + gestodene, 131 Female sterilization, Norplant implants, 359 laparoscopy, 283 Norplant-II implants, 359 minilaparotomy, 249, 351 Clinically important bleeding patterns, 57 Fertility, following estradiol cypionate + Continuation of contraceptive methods, medroxyprogesterone acetate, 307 determinants, 97 Contraceptive continuation in Benin, 97 Contraceptive practices, women requesting Gemeprost + RU 486, pregnancy termination, | pregnancy termination, 15 Gestodene, pharmacokinetics, 273 Contraceptive use, Gossypol, effect on spermatogenic cells (rat), LLL determinants, 287 bacterial vaginosis, 355 Contraceptive use in Bangladesh, 91 Hierarchical model of contraceptive use, 91 Copper IUD users, nitrites and L-citrulline levels, HIV-1 infected women, use of Norplant implants, 315 205 Copper T 380A IUD, 225 Hormonal emergency contraception, 153 © 1997 Elsevier Science Inc. All rights reserved ISSN 0010-7824/97/$17.00 655 Avenue of the Americas, New York, NY 10010 Pll SO010-7824(97)00091-7 384 Subject Index Contraception 1997;55:383-385 Hormone replacement therapy, transdermal Nonoxynol-9, estradiol + progestogens, 239 effect on sperm kinematics, PPP method for collection and recovery when vaginally administered, 261 Implant contraceptive, permeation into cervical mucus, 115 levonorgestrel, 7, 73, 81, 205, 359 Norethindrone-cholesterol implants, clinical study, norethindrone-cholesterol, 23 23 Injectable contraceptive, Norethisterone enanthate, estradiol cypionate + medroxyprogesterone pharmacokinetics, 373 acetate, 307 pharmacokinetics (rabbit, monkey, 373 estradiol enanthate + dihydroxprogesterone Norgestimate, pharmacokinetics, 273 acetophenide, 175 Norplant® implants, 7, 73, 205, 359 estradiol valerate + norethisterone enantate, 295 Norplant® implants insertion, anaphylactoid Intrauterine device ([UD), copper T 380A, 169, 225 reaction, 319 Norplant®-II implants, 359 L-citrulline level, copper IUD users, 315 Lactating women, use of copper T 380A IUD, 225 OC (oral contraceptive) use of progesterone vaginal ring, 225 OC use and exercise, effect on bone mineral Lactation, use of progestin-only contraceptive density, 87 methods, 347 OC use and liver disease, 145 Lactational Amenorrhea Method, 327, 337 OCs and breast cancer risk, 197 Laparoscopic female sterilization, 283 OCs and vascular disease, 267 Levonorgestrel concentrations, levonorgestrel rod OCs and venous thromboembolism, 189 implants, 81 OCs risk and recency of market introduction, 191 Levonorgestrel rod implants, Oral contraceptive (OC), clinical performance, 73 ethinyl estradiol + desogestrel, 219 levonorgestrel concentrations, 81 ethinyl estradiol + gestodene, 131 LHRH antagonist, antifertility effect (male rats), 369 ethinyl estradiol + levonorgestrel, 139 Lipid metabolism, ethinyl estradiol + norethisterone, 295 effect of estradiol valerate + norethisterone ethinyl estradiol + norgestrel, 245 enantate, 295 Ovulation Detection Method, natural family effect of ethinyl estradiol + desogestrel, 219 planning, 233 effect of ethinyl estradiol + norethisterone, 295 Liver disease and OC use, 145 Perimenopausal women, transdermal estradiol + Magnetic resonance imaging, interaction with progestogens, 239 CuT380A, 169 Pharmacokinetic interaction, ethinyl estradiol- Male infants, effect of buserelin, 311 amoxicillin (rabbit), 47 Medical abortions vs. surgical abortions, 67 Pharmacokinetics, Menstrual bleeding patterns, untreated women, 57 gestodene, 273 Methotrexate + misoprostol, comparison of various protocols, 159 norgestimate, 273 pregnancy terminations, 67 oral norethisterone enanthate, 373 Mifepristone (RU 486) oral norethisterone enanthate (rabbit, monkey), Minilaparotomy, female sterilization, 249, 351 373 Misoprostol, pregnancy termination, 165 Pituitary-adrenal function, effect of Norplant Myocardial infarction, OC users, 125 implants, 7 Pregnancy termination, antiprogestins + anordiol (rat), 35 Natural family planning, methotrexate + misoprostol, 67, 159 CUE® method, 233 misoprostol, 165 Ovulation Detection Method, 233 RU 486 + gemeprost, 1 Lactational Amenorrhea Method, 327, 337 Prethrombotic state, evaluation, 53 NET (norethindrone) Progestin-only contraceptives, use during lactation, NET:cholesterol pellets, Anuelle®, 23 347 Nitrites level, copper IUD users, 315 Progesterone-releasing vaginal ring, 225 Contraception Subject Index 385 1997;55:383-385 Quantitation of vaginally administered nonoxynol- Spermatogenic cells, effect of gossyol (rat), 183 9, 261 Surgical abortions vs. medical abortions, 67 Reactive nitrogen intermediates, copper IUD users, 315 Third generation OCs, 11, 125 Recency of market introduction, risk of OCs, 191 Transdermal estradiol + progestogens, Return of fertility, following estradiol cypionate + perimenopausal women, 239 medroxyprogesterone acetate, 307 RU 486, anti-implantation activity (monkey), 103 RU 486 + gemeprost, pregancy termination, | Vaginal ring, progesterone-releasing, 225 Vascular disease and OCs, 267 Second generation OCs, 125 Venous thromboembolic disease, OC users, 125 Side effects of OC use, effect of vitamin B,, 245 Venous thromboembolism and OC use, 189 Sperm kinematics, effect of nonoxynol-9, 209 Vitamin B,, effect on side effects of OC use, 245